Oral Healthcare Agreement

Syntopix Group plc
21 December 2007


For immediate release                                           21 December 2007



                               SYNTOPIX GROUP PLC

                         ('Syntopix' or 'the Company')


            Signs exclusive evaluation agreement in oral healthcare


Syntopix Group plc (AIM: SYN), the speciality pharmaceutical research and
development company focused on dermatological diseases, is pleased to announce
that it has signed a 12-month exclusive evaluation agreement with a major
consumer healthcare company. In this agreement, Syntopix will make available the
Company's library of compounds for assessment of the compounds' application in
oral healthcare.


The financial details of the agreement are confidential, although Syntopix will
receive an upfront payment at the start of the exclusivity period and further
payments for any compounds subject to additional evaluation. Commercialisation
of a compound would be subject to a licence agreement to be negotiated
separately.


Syntopix' core focus remains the development of prescription and OTC products
for the treatment of dermatological diseases. This agreement highlights the
Company's strategy of leveraging its compound library and intellectual property
into additional markets.


Dr Stephen Jones, Syntopix' Chief Executive Officer, said: 'This agreement in
oral healthcare broadens the number of potential markets that Syntopix is
targeting. Our core focus remains the development of products for the treatment
of dermatological diseases, though this agreement highlights our ability to
leverage our assets into new market segments.'





Enquiries

Syntopix Group plc                          + 44 (0) 845 125 9204
Dr Rod Adams, Chairman
Dr Stephen Jones, Chief Executive Officer

Buchanan Communications                     + 44 (0) 20 7466 5000
Mark Court
Catherine Breen

KBC Peel Hunt Ltd                           + 44 (0) 20 7418 8900
Capel Irwin



Notes to editors


About Syntopix Group plc


Syntopix is a group focused on the discovery and development of drugs for the
topical treatment of dermatological diseases. The company was founded in 2003 as
a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of
the leading experts in skin microbiology, with initial funding from The Wellcome
Trust.


Syntopix' strategy is to seek to reduce the risks and costs of drug discovery
and development by discovering novel uses for known compounds. The company
concentrates on compounds and combinations of compounds that have a history of
use in man; and that have well characterised properties, for example
antimicrobials and anti-inflammatories. The Group currently has 12 pending UK
patent applications.


Syntopix is currently concentrating on acne and Staphylococcus aureus infections
and has identified a pipeline of lead drug candidates that it intends to take
through pre-clinical and, as appropriate, clinical trials. The Group intends to
out-license products to commercial partners on obtaining proof of principle and
to seek co-development partnerships.


The Group is based at the Institute of Pharmaceutical Innovation in Bradford,
giving access to the expertise in skin biology, formulation and toxicology at
the universities of Bradford and Leeds.


Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group
plc), The Wellcome Trust Limited, University of Leeds Limited and Ridings Early
Growth Investment Company Limited. Syntopix joined the AIM market of the London
Stock Exchange in March 2006.


For further information please visit www.syntopix.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange